FDA Perspective on the Regulation of AI in Health Care and Biomedicine

Дата публикации: 21-01-2025 00:00:00

This Special Communication examines advances in the use of artificial intelligence in health care and biomedicine and how regulatory entities like the US Food and Drug Administration must evaluate how artificial intelligence operates within these sectors to develop appropriate regulatory frameworks.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Consumer Perspectives on Trust in and Benefits of AI in Health Care	0	6.27	04-08-2026
2	Public Acceptance of Artificial Intelligence in Health Care	0	10	04-08-2026
3	AI without the hype: What AML transformation means	0	9.07	06-10-2026
4	Patient Perspectives on AI-Drafted Electronic Portal Messages	0	13.29	07-07-2026
5	Developing medical devices with emerging technologies: trends, challenges, and future directions [version 3; peer review: 3 approved with reservations, 1 not approved]	0	9.1	17-08-2026
6	Atelier – Adapter la gouvernance de l’IA à des enjeux sectoriels : perspectives comparées	0	10	24-03-2026
7	ИИ в медицине: на пути к клиническому применению	0	10.96	03-08-2026
8	A new wave of disrupters takes on American health care	0	5	10-03-2026
9	When Patients Share Everything With An AI Chatbot	0	8.1	28-07-2026
10	Künstliche Intelligenz im Vorstandsrecht	0	10	14-07-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 5.14. Источник: jamanetwork.com.